Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Sentec ist ein schweizerisch-amerikanisches Medizintechnikunternehmen, das sich auf die Beatmungsmedizin spezialisiert. Seit seiner Gründung im Jahr 1999 verfolgt Sentec einen Deep-Tech-Ansatz, der auf fortschrittlicher Wissenschaft und avantgardistischen Technologien basiert, um Patienten mit Atemwegserkrankungen in allen Pflegebereichen
Swiss AviationSoftware is a 100% subsidiary of Lufthansa Technik, and along with our partners in the Digital Tech Ops Ecosystem, leads the digital transformation of the aviation industry in technical asset operation. As the developer of
Revolution Medicines is a late‑stage clinical oncology company developing novel targeted therapies for patients with RAS‑addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)